HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma
© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved..
Despite their unprecedented success in relapsed/refractory (R/R) large B-cell lymphoma (LBCL), anti-CD19 CAR T cells are associated with significant toxicity, and more than half of patients relapse. As monocytes emerged as key players in CAR therapy, we sought to evaluate the evolution of HLA-DR expression on monocytes (mHLA-DR) before and after commercial anti-CD19 CAR T-cell infusion in a large cohort (n = 103) of patients with R/R LBCL and its association with adverse events and treatment response. Cy-Flu-based lymphodepletion (LD) upregulated mHLA-DR in 79% of the cases, whereas in 2l% of cases (15 patients), the mHLA-DR level decreased after LD, and this decrease was associated with poorer outcome. Low mHLA-DR at day minus 7 (D-7) (<13 500 antibodies per cell) before CAR T-cell infusion correlated with older age, poorer performance status, higher tumor burden, and elevated inflammatory markers. With a median follow-up of 7.4 months, patients with low mHLA-DR D-7 exhibited a poorer duration of response and survival than the higher mHLA-DR D-7 group. For toxicity management, tocilizumab was more frequently used in the low-mHLA-DR D-7 group. These data suggest that monocyte dysregulation before LD, characterized by the downregulation of mHLA-DR, correlates with an inflammatory and immunosuppressive tumor environment and is associated with failure of anti-CD19 CAR T cells in patients with R/R LBCL. Modulation of these myeloid cells represents a promising field for improving CAR therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Blood advances - 7(2023), 5 vom: 14. März, Seite 744-755 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bourbon, Estelle [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
HLA-DR Antigens |
|---|
| Anmerkungen: |
Date Completed 06.03.2023 Date Revised 17.03.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1182/bloodadvances.2021006563 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339685956 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339685956 | ||
| 003 | DE-627 | ||
| 005 | 20231226003442.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/bloodadvances.2021006563 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1132.xml |
| 035 | |a (DE-627)NLM339685956 | ||
| 035 | |a (NLM)35439292 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bourbon, Estelle |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.03.2023 | ||
| 500 | |a Date Revised 17.03.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. | ||
| 520 | |a Despite their unprecedented success in relapsed/refractory (R/R) large B-cell lymphoma (LBCL), anti-CD19 CAR T cells are associated with significant toxicity, and more than half of patients relapse. As monocytes emerged as key players in CAR therapy, we sought to evaluate the evolution of HLA-DR expression on monocytes (mHLA-DR) before and after commercial anti-CD19 CAR T-cell infusion in a large cohort (n = 103) of patients with R/R LBCL and its association with adverse events and treatment response. Cy-Flu-based lymphodepletion (LD) upregulated mHLA-DR in 79% of the cases, whereas in 2l% of cases (15 patients), the mHLA-DR level decreased after LD, and this decrease was associated with poorer outcome. Low mHLA-DR at day minus 7 (D-7) (<13 500 antibodies per cell) before CAR T-cell infusion correlated with older age, poorer performance status, higher tumor burden, and elevated inflammatory markers. With a median follow-up of 7.4 months, patients with low mHLA-DR D-7 exhibited a poorer duration of response and survival than the higher mHLA-DR D-7 group. For toxicity management, tocilizumab was more frequently used in the low-mHLA-DR D-7 group. These data suggest that monocyte dysregulation before LD, characterized by the downregulation of mHLA-DR, correlates with an inflammatory and immunosuppressive tumor environment and is associated with failure of anti-CD19 CAR T cells in patients with R/R LBCL. Modulation of these myeloid cells represents a promising field for improving CAR therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a HLA-DR Antigens |2 NLM | |
| 700 | 1 | |a Sesques, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Gossez, Morgane |e verfasserin |4 aut | |
| 700 | 1 | |a Tordo, Jérémie |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrant, Emmanuelle |e verfasserin |4 aut | |
| 700 | 1 | |a Safar, Violaine |e verfasserin |4 aut | |
| 700 | 1 | |a Wallet, Florent |e verfasserin |4 aut | |
| 700 | 1 | |a Aussedat, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Maarek, Alizée |e verfasserin |4 aut | |
| 700 | 1 | |a Bouafia, Fadhela |e verfasserin |4 aut | |
| 700 | 1 | |a Karlin, Lionel |e verfasserin |4 aut | |
| 700 | 1 | |a Ghergus, Dana |e verfasserin |4 aut | |
| 700 | 1 | |a Golfier, Camille |e verfasserin |4 aut | |
| 700 | 1 | |a Lequeu, Hélène |e verfasserin |4 aut | |
| 700 | 1 | |a Lazareth, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Schwiertz, Vérane |e verfasserin |4 aut | |
| 700 | 1 | |a Viel, Sébastien |e verfasserin |4 aut | |
| 700 | 1 | |a Idlhaj, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Ghesquières, Hervé |e verfasserin |4 aut | |
| 700 | 1 | |a Monneret, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Bachy, Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Venet, Fabienne |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood advances |d 2016 |g 7(2023), 5 vom: 14. März, Seite 744-755 |w (DE-627)NLM268683263 |x 2473-9537 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2023 |g number:5 |g day:14 |g month:03 |g pages:744-755 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/bloodadvances.2021006563 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2023 |e 5 |b 14 |c 03 |h 744-755 | ||